Evidence map›Paper›PMID 33543421›Full record

ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2021

Benefit and danger from immunotherapy in myasthenia gravis.

Carmelo Rodolico, Giulia Nicocia, Valentina Damato, Giovanni Antonini, Rocco Liguori, Amelia Evoli

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Carmelo RodolicoDepartment of Clinical and Experimental Medicine, Unit of Neurology and Neuromuscular Diseases, University of Messina, Messina, Italy. crodolico@unime.it.ORCID http://orcid.org/0000-0003-2543-6356
Giulia NicociaDepartment of Clinical and Experimental Medicine, Unit of Neurology and Neuromuscular Diseases, University of Messina, Messina, Italy.
Valentina DamatoDepartment of Neurosciences, Catholic University, Rome, Italy.
Giovanni AntoniniDepartment of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Rocco LiguoriDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Amelia EvoliDepartment of Neurosciences, Catholic University, Rome, Italy.
Università Cattolica del Sacro Cuore · ITUniversity of Messina · ITAzienda Ospedaliera Sant'Andrea · ITInstitute of Neurological Sciences · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.

Indexed as

Myasthenia GravisB-LymphocytesHumansImmunologic FactorsImmunotherapyInfant, NewbornImmunologic FactorsCheckpoint inhibitorsEmerging therapyImmunotherapyRefractory myasthenia gravis

Identifiers

PMID33543421
PMCPMC7861968
OpenAlexW3127067613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.